Quarterly Results, Broker Conferences, Special IR Events FY2019 (April 2019-March 2020)

R&D Day in New York (12:30pm-4:00pm EST on November 14, 2019)

Webcast

All slides

Welcome and Opening Remarks, Sheelagh Cawley-Knopf, Head, R&D Global Portfolio Strategy

Takeda R&D Pipeline Narrative

Plasma-Derived Therapies Day in Covington, Georgia (11:15am-3:45pm EST on November 15, 2019)

Webcast *Webcast ends at 2:00pm

All slides

  • Plasma-Derived Therapies Overview, Julie Kim, President, Plasma-Derived Therapies Business Unit
  • Plasma-Derived Therapies R&D, Christopher Morabito, Head, R&D, Plasma-Derived Therapies
  • Covington Site Introduction, Carlos Soto, Covington Site Head

R&D Day and Plasma-Derived Therapies Day in Tokyo (11:00am-5:00pm JST on November 21, 2019)

Webcast

The presentation will be available prior to the meeting at 10:40am (JST) / 8:40pm (EST) on November 21.

Welcome and Opening Remarks, Sheelagh Cawley-Knopf, Head, R&D Global Portfolio Strategy

  • Plasma-Derived Therapies Overview, Julie Kim, President, Plasma-Derived Therapies Business Unit
  • Plasma-Derived Therapies R&D, Christopher Morabito, Head, R&D, Plasma-Derived Therapies
  • Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader, Christophe Weber, President & CEO
  • Translating Science into Highly Innovative, Life-changing Medicines, Andy Plump, President, R&D
  • Oncology and Cell Therapies with Spotlight on CAR-NK, Chris Arendt, Head, Oncology Drug Discovery Unit
  • Spotlight on Oncology Opportunities TAK-788, Rachael Brake, Global Program Leader, Oncology
  • Spotlight on Oncology Opportunities Pevonedistat, Phil Rowlands, Head, Oncology Therapeutic Area Unit
  • Rare Diseases & Gene Therapy, Dan Curran, Head, Rare Disease Therapeutic Area Unit
  • Spotlight on Orexin2R agonists, Deborah Hartman, Global Program Leader, Neuroscience
  • Therapeutic Area Focus in GI with Spotlight on Celiac Disease, Asit Parikh, Head, GI Therapeutic Area Unit

FY2019 Q2Results (released on October 31, 2019)

Consolidated Financial Statements submitted to TSE (Tokyo Stock Exchange)
(Without Independent Auditors report)
Click to download

Press Release

Data Book
Click to download

Earnings Release Presentation

For Investors and Analysts

A Competitive, Values-based, R&D-driven, Global Biopharmaceutical Leader
Christophe Weber, President & Chief Executive Officer
Andrew Plump, President, Research & Development
Costa Saroukos, Chief Financial Officer, and others
Click to download

For Media

A Competitive, Values-based, R&D-driven, Global Biopharmaceutical Leader
Christophe Weber, President & Chief Executive Officer, and others
Click to download


Supplementary materials for the financial statements
Underlying Core Reconciliation
Click to download

On-demand Webcast (Earnings meeting: For Media:4:15pm-5:15pm JST)

On-demand Webcast (Earnings meeting: For Investors & Analysts: 5:45pm-7:00pm JST)

On-demand Audio(Conference call 9:00pm-9:45pm JST)

IR meeting with analysts and investors with Julie Kim, President of Takeda's Plasma-Derived Therapies Business Unit (Held on October 10, 2019)

Morgan Stanley Healthcare Conference (Held on September 10, 2019 ET)

Audio
*Link to conference website

FY2019 Q1 Results (released on July 31, 2019)

Partial Correction of Financial Statements submitted to TSE (Tokyo Stock Exchange)
Click to download


Consolidated Financial Statements submitted to TSE (Tokyo Stock Exchange)

(Without Independent Auditor’s report)
Click to download


Press Release
 

Data Book
Click to download


Earnings Release Presentation

CONSOLIDATED FINANCIAL RESULTS FOR FY2019 Q1
Costa Saroukos, Chief Financial Officer
Click to download


Supplementary materials for the financial statements

Underlying Core Reconciliation
Click to download

Financial FAQs regarding FY2019 Q1 earnings
Click to download


Audio Conference Call

IR Seminar “Plasma-Derived Therapies Business” (Held on July 12, 2019)

Quarterly Results, Broker Conferences, Special IR Events Archive